Posted by Michael Wonder on 29 Apr 2023
Arcutis announces Canadian approval of Zoryve (roflumilast) cream 0.3% for treatment of plaque psoriasis in individuals 12 years and older
28 April 2023 - First Zoryve approval outside of the US marks key milestone for Arcutis.
Arcutis Biotherapeutics announced today that its next-generation topical PDE4 inhibitor therapy for plaque psoriasis, Zoryve (roflumilast) cream 0.3%, has received regulatory approval from Health Canada.
